Capacity Discipline Is Replacing Growth-at-Any-Cost

For approximately a decade, the chemicals industry operated on a model in which the answer to any question about market share was capacity addition. If a competitor was gaining share, you built more. If feedstock costs were low, you built more. If the cycle was at its peak and financing was available, you built. The result was a structural overcapacity in several chemical categories that persisted through 2024 and into 2025, suppressing margins and forcing producers to compete on price rather than on service, reliability, or market position.

The shift that is now underway is not a temporary adjustment. It is a fundamental reorientation of how major chemical producers are allocating capital and describing their business models to investors. The word "capacity" appears in a different context in 2026 earnings presentations than it did in 2022. In 2022, capacity meant growth. In 2026, capacity means quality, reliability, and selectivity. The shift has implications for procurement teams that have built their strategies around the assumption of structural supply surplus.

What BASF's Ludwigshafen Restructuring Actually Means

BASF's restructuring of its Ludwigshafen Verbund is the single most consequential capacity decision in European chemicals since the 2008 financial crisis. The site, which is the world's largest integrated chemical production complex, has been undergoing a programme of capacity rationalisation and product portfolio reduction that reflects BASF management's conclusion that full-scale commodity integration at European energy cost levels is no longer economically viable. The company has confirmed the closure of ammonia production, several MDI and TDI units, and multiple Verbund infrastructure assets at the site.

The restructuring is not driven by short-term cycle conditions. BASF's executive board has explicitly stated that European energy cost competitiveness relative to the US and Middle East has permanently changed the economics of certain chemical categories, and that the Ludwigshafen model of integrated commodity production cannot generate acceptable returns under those conditions. The language used by CEO Markus Kamieth in the Q1 2026 earnings call was notable for its directness: the company is not cutting capacity to wait for a better cycle. It is exiting categories where the European cost position is structurally disadvantaged.

Specialty Portfolios Are the Direction of Travel

Evonik's trajectory over the past four years illustrates the direction most European specialty chemical producers are moving. The company has divested its superabsorbents business, its methacrylates business, and its functional solutions division, using the proceeds to build positions in nutrition, care solutions, and performance materials. The 2026 portfolio is more concentrated and higher-margin than the 2022 portfolio. Revenue per employee and EBITDA margins per product are both higher. Volume growth is lower. Evonik's investor communications no longer emphasise capacity tonnes. They emphasise margin quality and customer concentration in high-barrier applications.

Lanxess has followed a comparable path, exiting engineering plastics and redirecting capital toward specialty additives, flavours and fragrances chemistry, and crop protection intermediates. Clariant's strategic review, completed in 2025, resulted in a similar conclusion: the commodity portions of the portfolio would be retained only where they generated scale advantages in specialty applications, not as standalone businesses. The pattern across these companies is consistent: commodity exposure is being reduced, specialty positioning is being deepened, and capital allocation is shifting from volume growth to return on capital employed.

Portfolio Direction by Producer Category, 2026

The Procurement Consequence: Structural Tightening Ahead

Procurement teams that have relied on structural oversupply to maintain leverage in supplier negotiations are entering a period in which that leverage will be structurally weaker. The rationalisation of European commodity capacity, the Middle Eastern supply disruption, and the slower-than-expected recovery of Chinese domestic capacity are all working in the same direction: less available supply, fewer swing producers willing to sell on spot, and more concentrated capacity in fewer hands.

This does not mean that buyers will be unable to source competitively. It means that the negotiating environment will change. Producers who have invested in specialty positioning will be more selective about which customers receive allocation and on what terms. Commodity producers who remain will be running at higher utilisation rates, with less buffer capacity to absorb spot demand or manage inventory build. The 2024 environment of excess supply and aggressive pricing is not returning quickly, and procurement strategies built on that assumption should be revised.